Valkit.ai Partners With Life Science Consulting for India Expansion

The system is mobile-first, requires no implementation fees.

Digital validation solutions firm Valkit.ai has announced a strategic partnership with Life Science Consulting (LSC), part of the Conval Group, to expand its operations in India.

The agreement, disclosed on August 17 through a joint release, names LSC as Valkit’s country partner for deploying its Generation 2 digital validation platform.

Valkit.ai, founded in Scotland and now based in Indiana, develops cloud-native validation tools aimed at replacing traditional paper-heavy processes in life sciences.

The company said its Gen-2 platform delivers “up to 80 percent reduction in lifecycle validation costs and 50 percent faster execution,” with deployment completed in four to six weeks compared with several months for legacy systems.

The system is mobile-first, requires no implementation fees, and is designed to comply with 21 CFR Part 11, EU Annex 11, and China’s NMPA guidelines.

“This collaboration with Life Science Consulting is a significant milestone for Valkit.ai. By combining our Gen-2 digital validation platform with LSC’s deep expertise and established presence in India, we aim to revolutionise validation processes across the region’s pharmaceutical sector,” said Hugh Devine, CEO of Valkit.ai.

Life Science Consulting has been operating out of Pune since 2012 and is backed by the Conval Group’s global network spanning Toronto, London, Istanbul, and the Netherlands. The company employs more than 70 validation consultants with over 300 years of combined industry experience.

“India’s pharmaceutical industry is at the heart of global drug supply chains. Our partnership with Valkit.ai brings cutting-edge digital validation capabilities to Indian manufacturers, enabling them to meet international regulatory expectations more efficiently,” said Arjun Guha Thakurta, Director at Life Science Consulting.

According to company figures, Conval Group has delivered over 3,000 validation projects and served more than 200 clients, including Novartis, Sandoz, Pfizer, Sanofi, Zentiva, Roche, GSK, and AstraZeneca. The group reported revenue growth of nearly 59 per cent in FY 2022–23.

The timing of the deal coincides with steady growth in Indian pharma exports.

Official data from Pharmexcil shows drug exports reached $30.47 bn in FY 2024-25, with the US accounting for $10.52 bn and Europe $5.77 bn. Industry forecasts suggest the figure could double by 2030, creating demand for faster and more compliant validation systems.

The LSC alliance is Valkit.ai’s second partnership in as many months, following its July collaboration with global consultancy CAI. The company is pursuing a partner-led expansion strategy to build scale across regulated markets in Asia, Europe, and North America.

Stay tuned for more such updates on Digital Health News